These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

389 related items for PubMed ID: 26317322

  • 1. Subgroup analysis of East Asians in RAINBOW: A phase 3 trial of ramucirumab plus paclitaxel for advanced gastric cancer.
    Muro K, Oh SC, Shimada Y, Lee KW, Yen CJ, Chao Y, Cho JY, Cheng R, Carlesi R, Chandrawansa K, Orlando M, Ohtsu A.
    J Gastroenterol Hepatol; 2016 Mar; 31(3):581-9. PubMed ID: 26317322
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of weekly paclitaxel with or without ramucirumab as second-line therapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma (RAINBOW-Asia): a randomised, multicentre, double-blind, phase 3 trial.
    Xu RH, Zhang Y, Pan H, Feng J, Zhang T, Liu T, Qin Y, Qin S, Yin X, Liu B, Ba Y, Yang N, Voon PJ, Tanasanvimon S, Zhou C, Zhang WL, Shen L.
    Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1015-1024. PubMed ID: 34626550
    [Abstract] [Full Text] [Related]

  • 3. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
    Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A, RAINBOW Study Group.
    Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
    [Abstract] [Full Text] [Related]

  • 4. Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.
    Shitara K, Muro K, Shimada Y, Hironaka S, Sugimoto N, Komatsu Y, Nishina T, Yamaguchi K, Segawa Y, Omuro Y, Tamura T, Doi T, Yukisawa S, Yasui H, Nagashima F, Gotoh M, Esaki T, Emig M, Chandrawansa K, Liepa AM, Wilke H, Ichimiya Y, Ohtsu A.
    Gastric Cancer; 2016 Jul; 19(3):927-38. PubMed ID: 26510663
    [Abstract] [Full Text] [Related]

  • 5. Effect of First-line S-1 Plus Oxaliplatin With or Without Ramucirumab Followed by Paclitaxel Plus Ramucirumab on Advanced Gastric Cancer in East Asia: The Phase 2 RAINSTORM Randomized Clinical Trial.
    Yoshikawa T, Muro K, Shitara K, Oh DY, Kang YK, Chung HC, Kudo T, Chin K, Kadowaki S, Hamamoto Y, Hironaka S, Yoshida K, Yen CJ, Omuro Y, Bai LY, Maeda K, Ozeki A, Yoshikawa R, Kitagawa Y.
    JAMA Netw Open; 2019 Aug 02; 2(8):e198243. PubMed ID: 31373648
    [Abstract] [Full Text] [Related]

  • 6. Exposure-response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.
    Kim TY, Yen CJ, Al-Batran SE, Ferry D, Gao L, Hsu Y, Cheng R, Orlando M, Ohtsu A.
    Gastric Cancer; 2018 Mar 02; 21(2):276-284. PubMed ID: 28634748
    [Abstract] [Full Text] [Related]

  • 7. Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW.
    Muro K, Cho JY, Bodoky G, Goswami C, Chao Y, Dos Santos LV, Shimada Y, Topuzov E, Van Cutsem E, Tabernero J, Zalcberg J, Chau I, Cascinu S, Cheng R, Hsu Y, Emig M, Orlando M, Fuchs C.
    J Gastroenterol Hepatol; 2018 Apr 02; 33(4):814-824. PubMed ID: 28960444
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma.
    Al-Batran SE, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov ON, Kim TY, Cunningham D, Rougier P, Muro K, Liepa AM, Chandrawansa K, Emig M, Ohtsu A, Wilke H.
    Ann Oncol; 2016 Apr 02; 27(4):673-9. PubMed ID: 26747859
    [Abstract] [Full Text] [Related]

  • 10. Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study.
    De Vita F, Borg C, Farina G, Geva R, Carton I, Cuku H, Wei R, Muro K.
    Future Oncol; 2019 Aug 02; 15(23):2723-2731. PubMed ID: 31234645
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
    Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J, REGARD Trial Investigators.
    Lancet; 2014 Jan 04; 383(9911):31-39. PubMed ID: 24094768
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.
    Yoon HH, Bendell JC, Braiteh FS, Firdaus I, Philip PA, Cohn AL, Lewis N, Anderson DM, Arrowsmith E, Schwartz JD, Gao L, Hsu Y, Xu Y, Ferry D, Alberts SR, Wainberg ZA.
    Ann Oncol; 2016 Dec 04; 27(12):2196-2203. PubMed ID: 27765757
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of ramucirumab for gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis.
    Ren R, Zhang Z, Zhai S, Yang J, Tusong B, Wang J.
    Eur J Clin Pharmacol; 2024 Nov 04; 80(11):1697-1714. PubMed ID: 39102039
    [Abstract] [Full Text] [Related]

  • 16. Ramucirumab for the treatment of metastatic gastric or gastroesophageal junction adenocarcinoma following disease progression on first-line platinum- or fluoropyrimidine-containing combination therapy in Japanese patients: a phase 2, open-label study.
    Yamaguchi K, Fujitani K, Nagashima F, Omuro Y, Machida N, Nishina T, Koue T, Tsujimoto M, Maeda K, Satoh T.
    Gastric Cancer; 2018 Nov 04; 21(6):1041-1049. PubMed ID: 29508095
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
    Bando H, Shimodaira H, Fujitani K, Takashima A, Yamaguchi K, Nakayama N, Takahashi T, Oki E, Azuma M, Nishina T, Hironaka S, Komatsu Y, Shitara K.
    Eur J Cancer; 2018 Mar 04; 91():86-91. PubMed ID: 29353164
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG).
    Jung M, Ryu MH, Oh DY, Kang M, Zang DY, Hwang IG, Lee KW, Kim KH, Shim BY, Song EK, Sym SJ, Han HS, Park YL, Kim JS, Lee HW, Lee MH, Koo DH, Song HS, Lee N, Yang SH, Choi DR, Hong YS, Lee KE, Maeng CH, Baek JH, Kim S, Kim YH, Rha SY, Cho JY, Kang YK.
    Gastric Cancer; 2018 Sep 04; 21(5):819-830. PubMed ID: 29427038
    [Abstract] [Full Text] [Related]

  • 20. Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review.
    Zhang X, Zhou L, Zhou C, Shen L.
    Adv Ther; 2024 Jun 04; 41(6):2112-2132. PubMed ID: 38619719
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.